Models of patient engagement for Alzheimer’s disease


Start Date
End Date
IMI2 - Call 5
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
2 043 000
EFPIA in kind
1 967 251
571 717
Total Cost
4 581 968


Dementia researchers are increasingly focusing their efforts on finding ways to prevent the onset of dementia symptoms in the first place, and for this they need to work with people who are still in the very earliest stages of the disease. The MOPEAD project aims to identify and test different models for engaging with this important group and determine which models work best in different situations. As well as adding to our understanding of the earliest stages of dementia, the project will facilitate recruitment for clinical trials and, most importantly, ensure that patients are able to access support from early on in their disease.

Achievements & News

Web search keywords can help spot early Alzheimer’s cases
January 2020

The earlier Alzheimer’s is diagnosed, the better the outlook. Though there is no medication that can stop or reverse the disease, there are medications and lifestyle changes that can help alleviate its effects. The problem is that people with memory problems tend to seek out help when their caretakers no longer feel able to cope with their worsening symptoms. ###The MOPEAD project research entailed a kind of pilot awareness-raising campaign that set out to test different ways of spotting sufferers in the population and directing them towards services that can diagnose and educate, and if necessary, treat them. In an interview with the IMI Programme Office, Assistant Professor Milica G. Kramberger from the University Medical Centre Ljubljana in Slovenia explains how the project used web searches, memory clinic open days, and visits to the doctor to identify people who could have Alzheimer’s.

‘The interesting thing we found was that we noticed, in Slovenia, that as a result of the awareness campaign, people started to worry about their own health, and started going to the doctor to get their memory checked a lot earlier,’ said Dr Kramberger. ‘In the past people went to the doctor only when their caregiver could not cope anymore.’

The MOPEAD research was carried out in Slovenia, Spain, the Netherlands, Germany and Sweden. The project also includes a feasibility study of cultural differences, healthcare system differences and the differences in models of patient engagement throughout Europe. The team will produce recommendations for policymakers based on their findings.

Read more

MOPEAD project begins patient recruitment
May 2018

IMI’s MOPEAD project has recruited its first patients in studies designed to identify people who may have early stage Alzheimer’s disease. Currently, many people with Alzheimer’s disease only receive a diagnosis when their disease is relatively advanced. The MOPEAD project is trialling different approaches, tools and mechanisms to engage communities ###and ensure people with Alzheimer’s disease receive the support they need as early as possible. The project is testing four broad strategies in Spain (where the first patients were recruited) as well as Germany, the Netherlands, Slovenia, and Sweden. People who take part in the study will undergo screening for mild cognitive impairment and, if needed, more extensive tests. If the tests show the person may have early stage Alzheimer’s disease, they will be offered support and resources including access to clinical trials as well as recommendations to improve their quality of life.

Participants Show participants on map

EFPIA companies
  • Astrazeneca AB, Södertälje, Sweden
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • European Institute Of Women'S Health Company Limited By Guarantee, Dublin, Ireland
  • Fundacio Ace, Barcelona , Spain
  • Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain
  • Karolinska Institutet, Stockholm, Sweden
  • Klinikum Der Universitaet Zu Koeln, Cologne, Germany
  • Stichting Vumc, Amsterdam, Netherlands
  • Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Asdm Consulting, Bruxelles, Belgium
  • Gmv Soluciones Globales Internet Sau, Tres Cantos, Spain
  • Modus Research And Innovation Limited, Dundee, United Kingdom
Patient organisations
  • Alzheimer Europe, Luxembourg, Luxembourg
  • Spomincica Alzheimer Slovenija Slovensko Zdruzenje Za Pomoc Pri Demenci, Ljubljana, Slovenia
Third parties
  • Region Stockholm, Stockholm, Sweden
Project leader
Laura Campo
Eli & Lilly